Life AI Net
Start
Archiv
Rechner
Verzeichnis
Newsletter
Anmelden
Deutsch
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Start
Archiv
Rechner
Verzeichnis
Newsletter
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Anmelden
Start
Archiv
Rechner
Verzeichnis
More
Live
Cell
Deep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation
Cell
Replaying germinal center evolution on a quantified affinity landscape
Cell
Xenophagocytosis blockade enhances interspecies chimerism
FierceBiotech
ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy
Endpoints News
#ADA26: Pfizer monthly shot shows effect on obesity, diabetes
Endpoints News
#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
Endpoints News
Lawmakers propose China restrictions; #ASCO26 recap; and more
FierceBiotech
‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
Amgen
Amgen: A Biotech Giant's Path to Recovery and Growth - AOL.com
Amgen
Amgen: A Biotech Giant's Path to Recovery and Growth - The Motley Fool
Novo Nordisk
Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026 - PR Newswire
Cell
Deep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation
Cell
Replaying germinal center evolution on a quantified affinity landscape
Cell
Xenophagocytosis blockade enhances interspecies chimerism
FierceBiotech
ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy
Endpoints News
#ADA26: Pfizer monthly shot shows effect on obesity, diabetes
Endpoints News
#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
Endpoints News
Lawmakers propose China restrictions; #ASCO26 recap; and more
FierceBiotech
‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
Amgen
Amgen: A Biotech Giant's Path to Recovery and Growth - AOL.com
Amgen
Amgen: A Biotech Giant's Path to Recovery and Growth - The Motley Fool
Novo Nordisk
Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026 - PR Newswire
Archiv
Dieser Artikel ist im Archiv nicht verfügbar.